The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia

Yasuhiro Taniguchi 1, Naoto Takahashi 2, Masatomo Miura 3, Chikara Hirase 4, Sanae Sueda 4, J. Luis Espinoza 5, Shinya Rai 1, Shoko Nakayama 1, Kentaro Serizawa 1, Takahiro Kumode 1, Yosaku Watatani 1, Yasuyoshi Morita 1, Hirokazu Tanaka 1 and Itaru Matsumura 1

Abstract:
We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD). He was treated with 50 mg dasatinib (DAS) once daily just before HD. The maximum plasma concentration of DAS was 227 ng/mL on a non-HD day and 46.9 ng/mL on a HD day. He was subsequently treated with 200 mg bosutinib (BOS) once daily. The plasma concentration of BOS changed from 74.5 ng/mL before HD to 58.8 ng/mL after HD. Our results indicate that close monitoring of the plasma tyrosine kinase inhibitor concentrations should be considered in CML patients with organ impairment.

Key words: dasatinib, bosutinib, hemodialysis, liver cirrhosis, plasma concentrations

(Intern Med Advance Publication)
DOI: 10.2169/internalmedicine.4871-20

Introduction

Chronic myeloid leukemia (CML) is a cancer of the blood cells, which is characterized by the increased and unregulated proliferation of myeloid cells in the bone marrow. Proliferating myeloid cells, which include mature granulocytes (neutrophils, eosinophils, and basophils) and immature precursors, accumulate in the blood, and their excessive proliferation is largely responsible for the symptoms associated with CML.

CML is a clonal disorder, originating from abnormal stem cells harboring a characteristic chromosomal abnormality called the Philadelphia chromosome, which is created via a translocation between the 9th and 22nd chromosomes. This chromosomal abnormality results in the formation of the BCR-ABL1 fusion gene, which generates the BCR-ABL protein. The BCR-ABL protein exhibits constitutive tyrosine kinase activity and affects the cell cycle and anti-apoptosis pathway, resulting in the unregulated proliferation that is characteristic of CML.

Most CML patients are diagnosed in the chronic phase (CP) of the condition, which lasts for 4-6 years. If CML-CP patients are not treated or the treatment is ineffective, then CML progresses to the accelerated phase (AP) followed by the blastic phase (BP), in which CML exhibits severe resistance to all treatments. Therefore, the prevention of disease progression is the most important factor affecting the outcomes of CML-CP treatment.

Tyrosine kinase inhibitor (TKI) treatment has greatly improved the prognosis of CML-CP (1). At present, TKI-treated CML patients rarely experience disease progression to AP or BP, and the life expectancy of such patients was found to be almost the same as that of an age-matched con-
control population (2).

On the other hand, the prognosis of CML patients with high Charlson comorbidity indices (CCI) was significantly worse than the prognosis of CML patients with low CCI (3). However, the efficacy of TKIs did not differ among these cohorts, suggesting that it is important to appropriately manage pre-existing complications and the toxicities of TKIs in CML patients. Therefore, appropriate dose adjustment of TKIs should be considered according to the patients’ backgrounds (including their comorbidities).

Both the efficacy and toxicity of TKIs are dependent on the plasma concentrations of the drugs (4-7). However, the plasma concentrations of TKIs are affected by concomitantly administered drugs and the functions of the liver and kidneys, which are involved in drug absorption, metabolism, and excretion. Thus, special attention should be paid to patients who are taking multiple drugs or that have organ dysfunction when prescribing TKIs.

We recently experienced a case involving a CML-CP patient with liver cirrhosis, who was undergoing hemodialysis (HD).

Little is known about the influence of HD on the plasma concentrations of TKIs in CML patients with renal insufficiency. We herein report on the changes in the plasma concentrations of dasatinib (DAS) and bosutinib (BOS) that occurred in the abovementioned patient and review the effects of HD on the plasma concentrations of TKIs.

### Table 1. Laboratory Findings in This Case.

| CBC         | Chemistry     | Coagulation |
|-------------|---------------|-------------|
| RBC         | AST 39 U/L    | PT 84.4 %   |
| Hb          | ALT 16 U/L    | APTT 35.8 sec |
| Hct         | ALP 441 U/L   |             |
| Plt         | LDH 364 U/L   |             |
| WBC         | T-Bil 0.5 mg/dL |           |
| Myeloblasts | TP 7.5 g/dL   |             |
| Myelocytes  | Alb 3.7 g/dL  |             |
| Metamyelocytes | BUN 26 mg/dL |             |
| Stab neutrophils | Cre 4.48 mg/dL |           |
| Seg. neutrophils | UA 4.2 mg/dL |             |
| Eosinophils | Glu 91 mg/dL  |             |
| Basophils   | CRP 0.95 mg/dL|             |
| Monocytes   |               |             |
| Lymphocytes |               |             |
| NAP rate    | 7 %           |             |

CBC: complete blood count; RBC: red blood cells; Hb: hemoglobin; Hct: hematocrit; Plt: platelets; WBC: white blood cells; Seg: neutrophils: segmented neutrophils; NAP: neutrophil alkaline phosphatase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALP: alkaline phosphatase; LDH: lactate dehydrogenase; T-Bil: total bilirubin; TP: total protein; Alb: albumin; BUN: blood urea nitrogen; Cre: creatinine; UA: uric acid; Glu: glucose; CRP: C-reactive protein; PT: prothrombin time; APTT: activated partial thromboplastin time; ICG-R15: indocyanine green retention rate at 15 min

Case Report

A 64-year-old male was referred to Kindai University Hospital with leukocytosis. He had chronic kidney disease (CKD) due to chronic glomerulonephritis, and had been undergoing HD three times a week since 1985. In addition, he had liver cirrhosis (Child-Pugh classification: class A), and his indocyanine green retention rate at 15 minutes was 17%. He had a history of acute hepatitis B, and serological tests produced the following results: HBsAg (-), HBsAb (+), and HBV-DNA (-). At his first visit, he was free from splenomegaly, ascites, fever, night sweats, and general fatigue. His laboratory data are shown in Table 1. A bone marrow aspirate specimen revealed marked hypercellularity with myeloid hyperplasia, but no dysplasia or increase in the blast ratio was seen. Karyotyping of his bone marrow cells produced the following result: t(9;22)(q34;q11.2). No other cytogenetic abnormalities were detected. The patient was diagnosed with CML-CP, and DAS treatment was started at a dose of 50 mg once a day.

One week after the start of the DAS treatment, we had the drug’s plasma concentration measured by MASIS Inc. (MASIS Inc., Food and Drug Nano Analysis, Aomori, Japan) on two consecutive days (the patient was on HD on the 1st day and off HD on the 2nd day). DAS was given to the patient just before HD, and its maximum plasma concentration (Cmax) was 46.9 ng/mL at 2 hours. In contrast, its concentration (Cmax) was 46.9 ng/mL at 2 hours [AUC (0-12)] was 257 ng·h/mL on the HD day and 793 ng·h/mL on the non-HD day (Figure). However, 2 weeks after the start of the DAS treatment, mild bilateral pleural effusion and pulmonary hypertension (PH) (45 mmHg) were detected on an X-ray examination and cardiac...
Figure. The plasma concentrations of dasatinib (DAS) before and after hemodialysis (HD) in our patient. The DAS concentration did not increase on the day of HD. The DAS concentration was markedly elevated on the non-HD day.

ultrasonography. Although we considered that the PH had been caused by chronic heart failure, rather than the DAS treatment, because DAS had only been administered for a short period, we were worried about the possibility that DAS might further worsen the PH. Thus, we replaced the DAS with 200 mg BOS once a day.

After the start of the BOS treatment, we measured the plasma concentration of BOS at Akita University (Akita, Japan). BOS was administered just before HD, and its plasma concentration at 2 hours was 273 ng/mL, whereas its plasma concentration on the non-HD day was 180 ng/mL. The AUC (0-12) of BOS was 912 ng·h/mL on the HD day and 851 ng·h/mL on the non-HD day. However, the plasma concentration of BOS fluctuated markedly from 85.5 to 273 ng/mL during the HD. Therefore, we next examined whether HD removes BOS by examining its plasma concentrations before and after HD without administering BOS. As a result, it was found that the plasma concentration of BOS was 74.5 ng/mL before the HD and 58.8 ng/mL after the HD. Thus, we considered that BOS was only partially removed by HD and that the dosage of BOS was appropriate for this patient. He continued receiving BOS at the same dosage and achieved a BCR-ABL international scale value of <10% at 3 months (the optimal response according to the ELN2013 (8)) after the start of the BOS treatment.

Discussion

The liver plays a central role in the pharmacokinetics of most drugs by regulating not only their metabolism and elimination, but also their absorption and distribution. DAS is mainly metabolized by CYP3A4 in the liver. Most (85%) of its metabolites are excreted in feces, and only 4% are excreted in urine (9). Therefore, it is assumed that the plasma concentration of DAS is increased by hepatic dysfunction. However, according to the packaging data for DAS submitted to the US FDA, the mean Cmax and AUC values of DAS are lower in patients with hepatic dysfunction. As a result, dose adjustment, especially dose reduction, is not necessary to consider during DAS treatment, even for patients with hepatic dysfunction (9). In contrast, in Japan it is recommended that DAS should be prescribed with caution to patients with hepatic dysfunction due to the risk of overprescription (10). Our patient had mild liver cirrhosis (Child-Pugh class A). In addition, he was being treated with carvedilol for heart failure, which is also metabolized by CYP3A4, and it was assumed that it would increase the serum concentration of DAS through competitive metabolization. Therefore, we prescribed DAS at a daily dose of 50 mg. However, even though only a half-dose was administered, the Cmax of DAS was elevated (227 ng/mL), and its AUC was 793 ng·h/mL on the non-HD day. When DAS was given to Japanese patients with solid tumors at a daily dose of 100 mg, its Cmax was 140 ng/mL, and its AUC was 538 ng·h/mL (10). Although we have to consider the effects of carvedilol, these results suggest that dose reduction is required for CML patients with liver dysfunction who are treated with DAS.

BOS is also primarily metabolized by CYP3A4 in the liver, and its plasma concentration is elevated by liver dysfunction (11). When BOS was taken at a daily dose of 200 mg, its mean Cmax in Western healthy controls was 34.0 ng/mL, whereas its mean Cmax in Child-Pugh A, B, and C patients was 86.7 ng/mL, 68.4 ng/mL, and 58.8 ng/mL, respectively (11). In our patient, the Cmax of BOS was 273 ng/mL on the HD day and 180 ng/mL on the non-HD day, which were much higher than the levels seen in the healthy controls and Child-Pugh A patients. Thus, we considered that the concomitant use of carvedilol was also responsible for the high Cmax of BOS observed in our patient.

The AUC of BOS increased by 35% in patients with mild renal dysfunction and by 60% in patients with severe dys-
function (12). As for the mechanism responsible for this, a previous study showed that the activity of cytchrome P450, including CYP3A4, in the liver (13) and intestines (14) was low in animals with CKD. Also, CYP3A4 activity was reported to be low in patients with renal dysfunction (15). These findings suggest that the reduced CYP3A4 activity seen in patients with renal dysfunction might result in excessive increases in the plasma concentration of BOS.

In addition to liver dysfunction, our patient was undergoing HD, which might have removed the administered TKIs from his plasma. At present, there are few reports about TKI treatment in HD patients. In previous cases, imatinib was given to 7 HD patients (16-20); in only one case, the plasma concentration of imatinib was measured, and there was no difference between before and after HD (16). Moreover, apparent toxicities of the imatinib for the HD patients have been rarely reported so far (Table 2), which suggests that it is not necessary to modify the dose of imatinib given to CML patients on HD. In addition, there have been 3 reports about the treatment of CML with nilotinib (NIL) in 3 HD patients (20). There were no significant differences between the plasma NIL concentrations observed before and after HD. This suggests that NIL is not eliminated by HD, and dose reduction of NIL is not necessary for patients on HD. As for DAS, we could only find three reports about its use in HD patients (21-23). In the first case, the patient exhibited a partial cytogenetic response without any marked toxicities (21). In the second case, although only 50 mg DAS was administered on the HD days, the DAS treatment was stopped immediately because it exacerbated the patient’s pleural effusion (22). In these two cases, the effects of HD on the plasma DAS concentration were not evaluated. In the third case, the plasma concentration of DAS was not affected by HD (23). On the other hand, in the present case the Cmax of DAS was 46.9 ng/mL on the HD day, and it increased to 227 ng/mL on the following (non-HD) day, suggesting that DAS was markedly eliminated by HD. We administered DAS just before HD, and its Cmax was recorded during the HD. In contrast, the DAS concentration was recorded at its trough level in the previously reported case (23), which might have masked the impact of HD on the plasma concentration of DAS. In contrast, the Cmax of BOS was 273 ng/mL on the HD day and 180 ng/mL on the non-HD day. In addition, we confirmed that the plasma concentration of BOS only partially decreased from 74.5 ng/mL to 58.8 ng/mL after HD. These results imply that BOS was only partially removed by HD.

**Conclusion**

We measured the plasma concentrations of DAS and BOS in a CML patient with renal failure requiring HD and liver cirrhosis. The concentrations of DAS and BOS are affected by liver function. In addition, we found that in our patient DAS was markedly eliminated by HD, while BOS was scarcely eliminated. Thus, in CML patients with renal and hepatic impairment it is necessary to measure TKI concentrations in order to optimize such drug treatment.

**Author’s disclosure of potential Conflicts of Interest (COI).**

Itaru Matusura: Honoraria, Bristol-Myers Squibb, Novartis, Otsuka and Pfizer. Naoto Takahashi: Honoraria, Novartis, Otsuka and Pfizer.
Statement of Ethics
Informed consent was obtained from the patient’s family for the publication of this case report.

Funding Sources
The authors received no specific funding for this work.

Authors’ Contributions
Y.T. wrote the manuscript with support from C.H., and J.L.E., N.T., and M.M. performed the TKI measurements. S.S., S.R., S., N., K.S., T.K., and Y.W. were involved in treating the patient and provided the clinical data. Y.M., H.T., and I.M. were responsible for the final approval of the manuscript. All of the authors have reviewed and approved the final draft.

References
1. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417, 2006.
2. Lang K, McGarry LJ, Huang H, Dorer D, Kaufman E, Knopf K. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data. Clin Lymphoma Myeloma Leuk 16: 275-285.e1, 2016.
3. Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Blood 126: 42-49, 2015.
4. Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 52: 1024-1029, 2011.
5. Giles FJ, Yin OQ, Sallas WM, le Coutre PD, Woodman RC, Ottmann OG, et al. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia. Eur J Clin Pharmacol 69: 813-823, 2013.
6. Wang X, Roy A, Hochhaus A, Kantarjian HM, Chen TT, Shah NP. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study. Clin Pharmacol Ther 10: 85-97, 2013.
7. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patients. Leuk Res 48: 84-91, 2016.
8. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122: 872-884, 2013.
9. Sprycel® (dasatinib) [package insert]. Bristol-Myers Squibb Company [Internet]. [cited 2019 Nov 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s78lbl.pdf.
10. Sprycel® (dasatinib) [package insert]. Bristol-Myers Squibb Company [Internet]. [cited 2019 Nov 19]. Available from: https://www.info.pmda.go.jp/go/interview/1/670605_4291020F1027_1_013_1F.pdf.
11. Abbas R, Chalson S, Leister C, El Gaaloul M, Sonnichsen D. Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects. Cancer Chemoth Pharmacol 71: 123-132, 2013.
12. Bosulif (bosutinib) [package insert]. Pfizer [Internet]. [cited 2019 Nov 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/20334s007s008lbl.pdf.
13. Leblond FA, Guevin C, Demers C, Pellerin I, Gascon-Barré M, Pichette V. Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12: 326-332, 2001.
14. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, Pichette V. Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13: 1579-1585, 2002.
15. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 73: 427-434, 2003.
16. Pappas P, Karavasillis V, Briasoulis E, Pavlidis N, Marselos S. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Cancer Chemoth Pharmacol 56: 358-360, 2005.
17. Ozdemir E, Kok Y, Kansu E. Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis. Am J Hematol 81: 474, 2006.
18. Wada Y, Ogata H, Misawa S, Shimada A, Kinugasa E. A hemodialysis patient with primary extra-gastrointestinal stromal tumor: favorable outcome with imatinib mesylate. Intern Med 51: 1561-1565, 2012.
19. Niikura R, Serizwa T, Yamada A, Yoshida S, Tanaka M, Hirata Y, et al. Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis. Case Rep Gastroenterol 10: 17-23, 2016.
20. Onaka T, Takahashi N, Miura M, Yonezawa A, Imada K, Sawada K. Pharmacokinetics of nilotinib in imatinib-resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure. Am J Hematol 87: 451, 2012.
21. Holstein SA, Stokes JB, Hohl RJ. Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. Leuk Res 33: 344-347, 2009.
22. Shibazaki S, Tsuda K, Araki M, Yamasaki M, Miura K. A case of long-term survival from chronic myeloid leukemia in a hemodialysis patient receiving imatinib and experiencing cardioxicity with dasatinib. Nihon Toseki Igakkai Zassi (Journal of Japanese Society of Dialysis Therapy) 48: 713-718, 2015 (in Japanese).
23. Mori J, Oshima K, Tanimoto T, Ishizuka H, Kimura S, Miura M, et al. Pharmacokinetics of dasatinib in a hemodialysis patient with chronic myeloid leukemia and chronic kidney disease. Int J Hematol 2020, in press.